Sangamo Therapeutics, Inc. (SGMO)
- Previous Close
0.5030 - Open
0.5200 - Bid 0.5162 x 200
- Ask 0.5223 x 200
- Day's Range
0.5030 - 0.5339 - 52 Week Range
0.2900 - 1.6700 - Volume
662,120 - Avg. Volume
2,415,592 - Market Cap (intraday)
107.441M - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4800 - Earnings Date Apr 29, 2024 - May 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
www.sangamo.comRecent News: SGMO
Performance Overview: SGMO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SGMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SGMO
Valuation Measures
Market Cap
107.44M
Enterprise Value
64.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
1.30
Enterprise Value/Revenue
0.37
Enterprise Value/EBITDA
-0.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-146.30%
Return on Assets (ttm)
-17.60%
Return on Equity (ttm)
-136.47%
Revenue (ttm)
176.23M
Net Income Avi to Common (ttm)
-257.83M
Diluted EPS (ttm)
-1.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
81M
Total Debt/Equity (mrq)
45.97%
Levered Free Cash Flow (ttm)
-90.74M